FDA's medical advertising hotline
The agency has received 36 calls since the telephone lines become operational on Sept. 16, Medical Staff Director Peter Rheinstein tells a Sept. 30 Food and Drug Law Institute meeting on device advertising. He said that "two or three or four [calls] were on drug advertising or biologic advertising," and a few calls were from physicians who were concerned about the ethics of drug companies giving them something for enrolling in studies. The first article announcing the hotline appears in the Oct. 2 issue of The Journal of the American Medical Association. . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth